Cost Effectiveness Analysis of Antibiotic Regimens Used in Outpatient Treatment of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)Acevski Stevche1*, Minov Jordan2, Sterjev Zoran3, Zareski Rubin3, Kapedanovska Nestorovska Aleksandra3 and Suturkova Ljubica3
- *Corresponding Author:
- Acevski Stevche
Alkaloid AD Skopje, blvd. “Aleksandar Makedonski” No 12
1000 Skopje, R. Macedonia
Tel: 389 72 239 322
E-mail: [email protected]
Received date: August 24, 2016; Accepted date: October 18, 2016; Published date: October 21, 2016
Citation: Stevche A, Jordan M, Zoran S, Rubin Z, Aleksandra KN, et al. (2016) Cost Effectiveness Analysis of Antibiotic Regimens Used in Outpatient Treatment of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD). Adv Pharmacoepidemiol Drug Saf 5:212. doi: 10.4172/2167-1052.1000212
Copyright: © 2016 Stevche A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Allocation of the resources in health care and finding a way how to prioritize spending within health care systems are hot issue, even in the developed countries. Introduction of new medical products and technologies is one important driver for increased health care costs. COPD is among top five causes of morbidity and mortality worldwide. The aim of this study is to evaluate cost effectiveness of antimicrobial regiments for treatment of acute exacerbation of COPD. Cost effectiveness analysis was performed based on data from two published observational, “real world” studies carried in Institute for occupational Health of Macedonia. Methodology is based on calculation of ICER in as many steps as needed until all exclusion criteria`s are met. All ICER`s are interpreted using cost effectiveness plane. Amoxicillin with clavulanic acid and cefuroxime dominated over other antibiotic regiments. Doxycycline, cefuroxime, cefpodoxime and moxifloxacin are cost-effective alternatives. When deciding, size of the available budget and patient’s willingness to pay will be key factors. The results of this study provide data and useful information which antibiotic will give best expected outcomes, with least produced costs.